NBY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
NovaBay Pharmaceuticals Inc (NBY) is not a good buy at this moment for a beginner investor with a long-term strategy. The financial performance is weak, technical indicators are bearish, and there are no positive catalysts or significant trading signals to support an immediate investment decision.
The MACD is positive and expanding, indicating some bullish momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels (S1: 1.593), which suggests further downside risk.
NULL identified. No recent news, no significant hedge fund or insider activity, and no recent congress trading data.
Weak financial performance in Q3 2025, with a significant drop in net income (-41.68% YoY) and EPS (-88.54% YoY). The stock is trading below key support levels, and there are no positive trading signals or trends.
In Q3 2025, revenue remained flat YoY at $521,000. Net income dropped significantly to -$1,293,000 (-41.68% YoY), and EPS declined sharply to -$0.22 (-88.54% YoY). Gross margin increased slightly to 8.06%. Overall, the financial performance is weak and does not support a long-term investment.
No data available for analyst ratings or price target changes.
